Search results
Results from the WOW.Com Content Network
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
144 674.18 g·mol −1 Cosibelimab , sold under the brand name Unloxcyt , is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma . [ 1 ] It is a programmed death ligand-1 (PD-L1) blocking antibody.
[medical citation needed] Besides, hyaluronidase is a recommended antidote for vinca alkaloid overdose or extravasation. [12] Hyaluronidase can be injected to dissolve hyaluronic acid type dermal fillers and is the best treatment option for those looking at dissolving lip filler or dealing with related complications. [13]
After introducing medically assisted treatment in 2013, Seppala saw Hazelden’s dropout rate for opiate addicts in the new revamped program drop dramatically. Current data, which covers between January 1, 2013 and July 1, 2014, shows a dropout rate of 7.5 percent compared with the rate of 22 percent for the opioid addicts not in the program.
Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer. [4] [7] It is taken by mouth.[4]The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides ...
Participants were randomized 1:1 to receive either trastuzumab deruxtecan or trastuzumab emtansine by intravenous infusion every three weeks until unacceptable toxicity or disease progression. [16] Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease. [16]